Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Hilal Saraç"'
Autor:
hilal saraç canbolat
Publikováno v:
Turkish Journal of Oncology.
Publikováno v:
Turkish Journal of Oncology / Türk Onkoloji Dergisi. 2023 Supplement, Vol. 38, p186-186. 1/2p.
Autor:
Mert Kilic, Umit Ince, Nathan A. Lack, Tarık Esen, Yesim Saglican, Hilal Saraç, Ceren Seref, Bilgen Coskun, Ömer Acar, Metin Vural
Publikováno v:
The ProstateREFERENCES. 82(1)
BACKGROUND The detection rate of clinically significant prostate cancer has improved with the use of multiparametric magnetic resonance imaging (mpMRI). Yet, even with MRI-guided biopsy 15%-35% of high-risk lesions (Prostate Imaging-Reporting and Dat
Inhibiting the androgen receptor (AR) is the standard of care to treat metastatic or recurrent prostate cancer. While treatment is initially effective, the cancer almost always develops resistance and progresses into a lethal castrate-resistant prost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::280c729f04f968148c5709d52f25c197
https://doi.org/10.1016/b978-0-12-821310-0.00007-3
https://doi.org/10.1016/b978-0-12-821310-0.00007-3
Autor:
Deborah H. Anderson, David N. Brindley, Artem Cherkasov, Mackenzie L. Coatham, E. Dadachova, Shoukat Dedhar, Vincenzo Giambra, Juha P. Himanen, Michael Jewer, Madhuri Koti, Nathan A. Lack, Xueqing Lun, Paul C. McDonald, Jennifer M. Nagel, Dimitar B. Nikolov, Alisha Poole, Lynne-Marie Postovit, Afshin Raouf, Stephen M. Robbins, Hilal Saraç, Donna L. Senger, Noor Shakfa, Peter M. Siegel, D. Robert Siemens, Francesco Tamiro, Josie Ursini-Siegel, Andrew P. Weng
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05037e925fddfa0d06394838a5c405b2
https://doi.org/10.1016/b978-0-12-821310-0.09987-3
https://doi.org/10.1016/b978-0-12-821310-0.09987-3
Autor:
Akane Kawamura, Nathan A. Lack, James S. O. McCullagh, Tunç Morova, Tamer T. Onder, Hilal Saraç, Anıl Kaplan, Ahmet Cingoz, Tugba Bagci-Onder, Elisabete Pires
Publikováno v:
Oncogene
Androgen deprivation therapy (ADT) is the standard care for prostate cancer (PCa) patients who fail surgery or radiotherapy. While initially effective, the cancer almost always recurs as a more aggressive castration resistant prostate cancer (CRPC).
Autor:
Tarık Esen, Nathan A. Lack, Ezgi Özkurt, Can Alkan, Hilal Saraç, Mehmet Somel, Ömer Acar, Gulfem Demir
Publikováno v:
BMC Cancer
Background: Synchronous multifocal tumours are commonly observed in urothelial carcinomas of the bladder. The origin of these physically independent tumours has been proposed to occur by either intraluminal migration (clonal) or spontaneous transform
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4002757b1b01e840a828b5bfa0288d9
https://hdl.handle.net/11693/26530
https://hdl.handle.net/11693/26530